GYKI 38233
Alternative Names: B GYKI 38233; Restacorin; TYB 3823Latest Information Update: 07 Mar 2007
At a glance
- Originator IVAX Drug Research Institute
- Developer Biogal; IVAX Drug Research Institute
- Class Class Ic antiarrhythmics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 03 Dec 1998 TYB 3823 is now called GYKI 38233
- 03 Dec 1998 No-Development-Reported for Arrhythmias in Germany (IV)